Copper tripeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H24N6O4 | Free tripeptide, without copper |
| Molecular weight | About 340 g/mol | Peptide portion only |
| Appearance | Blue to violet powder | Color from copper coordination |
| Solubility | Soluble in water | pH influences dissolution |
| Common synonyms | Copper tripeptide-1, Cu-GHK | Seen on ingredient labels |
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
These include agents that increase insulin release (sulfonylureas), agents that decrease absorption of sugar from the intestines (acarbose), agents that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4) that inactivates incretins such as GLP-1 and GIP (sitagliptin), agents that make the body more sensitive to insulin (thiazolidinedione) and agents that increase the excretion of glucose in the urine (SGLT2 inhibitors). When insulin is used in type 2 diabetes, a long-acting formulation is usually added initially, while continuing oral medications. Some severe cases of type 2 diabetes may also be treated with insulin, which is increased gradually until glucose targets are reached.
=== Contestants === 1st - Blayre Wright, Bakery Owner from Lancaster, Pennsylavania 2/3/4th - Zac Mercer, Bakery Owner from Denver, Colorado 2/3/4th - Lauren Rodgers, Bakery Owner from Olympia, Washington 2/3/4th - Jill Davis, Bakery Owner from Owosso, Michigan 5th - Kristi Descher, Pastry Chef from Valencia, California 6th - Alexey Ivanov, Home Baker from Brooklyn, New York 7th - Lola Forbes, Bakery Co-Owner from Mesa, Arizona 8th - Maricsa Trejo, Bakery Owner from Richardson, Texas 9th - Justin Dominguez, Bakery Owner and Cake Artist from San Antonio, Texas 9th - Margarita Garcia, Pastry Chef from Miami, Florida 11th - Marcus Brackett, Self-Taught Baker from Rockville, Maryland 12th - AJ DeDiego, Home Baker from Atlanta, Georgia
Diabulimia (a portmanteau of diabetes and bulimia), also known as ED-DMT1 (eating disorder-diabetes mellitus type 1) in the US or T1ED (type 1 eating disorder) in the UK, is an eating disorder in which people with type 1 diabetes deliberately give themselves less insulin than they need or stop taking it altogether for the purpose of weight loss. Diabulimia is not recognized as a formal psychiatric diagnosis in the DSM-5. Because of this, some in the medical or psychiatric communities use the phrases "disturbed eating behavior" or "disordered eating behavior" (DEB in both cases) and disordered eating (DE) are quite common in medical and psychiatric literature addressing patients who have type 1 diabetes and manipulate insulin doses to control weight along with exhibiting bulimic behavior. Diabulimia is caused by a range of factors relating to body image, the regular use of insulin, and emotional well-being. Insulin can cause weight gain, and a person who restricts insulin may lose weight. Insulin restriction can lead to the common symptoms of uncontrolled hyperglycemia, which risks complications and a shorter life expectancy. Treatment involves cognitive behavioral therapy, and other support services offered by a multidisciplinary team who work both in diabetes medicine and on eating disorders. Diabulimia is most common in young people, and most of the severe cases tend to occur in women. Research into effective management strategies is ongoing, with a growing medical consensus on the importance of early intervention with specialist teams.
To provide a deeper scientific foundation for MD students, Einstein hosts the five-year Clinical Research Training Program (CRTP). The CRTP confers a Master of Science and requires an additional year of courses on clinical research methods. Students may also graduate with distinction in research for their medical degree. With Yeshiva's Benjamin N. Cardozo School of Law, Einstein offers both a certificate and Master of Science in Bioethics. The program covers clinical bioethics consultation, healthcare ethics policy, and human subject research. Einstein also offers MD students a joint Master of Public Health degree with the City University of New York (CUNY). This Einstein-CUNY MD-MPH program lasts five years.
Sources: en.wikipedia.org
The FDA has identified that breast implants may be associated with a rare form of cancer called anaplastic large-cell lymphoma (ALCL), which some experts believe is believed to be associated with chronic bacterial inflammation. Similar ALCL phenomena have been seen with other types of medical implants including vascular access ports, orthopedic hip implants, and jaw (TMJ) implants. The causal association between breast implants and ALCL was conclusively established in December 2013, when researchers at MD Anderson Cancer Center published a study of 60 women with breast implants who were diagnosed with ALCL in the breast. In 2015, plastic surgeons published an article reviewing 37 articles in the literature on 79 patients and collected another 94 unreported cases, resulting in 173 women with breast implants who had developed ALCL of the breast. They concluded that "Breast implant-associated ALCL is a novel manifestation of site- and material-specific lymphoma originating in a specific scar location, presenting a wide array of diverse characteristics and suggesting a multifactorial cause." They stated that "There was no preference for saline or silicone fill or for cosmetic or reconstructive indications." Where implant history was known, the patient had received at least one textured-surface device. In 2016, the World Health Organization (WHO) officially recognized BIA-ALCL. As of April 2022, the FDA has received 1,130 global medical device reports (MDRs) of BIA-ALCL, including 59 deaths.
=== Critical response === On Rotten Tomatoes, the first season has an approval rating of 89% based on 38 reviews, with an average rating of 7.61/10. The website's critical consensus reads: "A stellar series perfect for anyone looking for a little hope, Stargirl is delightful fun the whole family can enjoy". On Metacritic it has a weighted average score of 68 out of 100 based on 8 reviews, indicating "generally favorable reviews". Brian Lowry of CNN described the series as "hardly seeks to reinvent the wheel, or even expand the mold. Still, its mix of solid characters, clever writing and youthful exuberance casts a brighter light than most". Daniel Fienberg of The Hollywood Reporter gave a review, calling it "derivative, but should fill the superhero-origin-story-shaped hole in your heart" and wrote: "The result is that a show that is frequently derivative to the point of distraction might actually fill a need for viewers able to concentrate on its occasional charms until better superhero shows return". On Rotten Tomatoes, the second season holds an approval rating of 100% based on 5 reviews, with an average rating of 8.2/10.
There are two more enzymes that catalyze the conversion of versicolorin A to demethylsterigmatocystin: AflN, an oxidase and AflM, a reductase. These enzymes use both molecular oxygen and two NADPH's to dehydrate one of the hydroxyl groups on the anthraquinone and open the quinine with the molecular oxygen. Upon forming the aldehyde in the ring opening step, it is oxidized to form the carboxylic acid and subsequently a decarboxylation event occurs to close the ring, forming the six-member ether ring system seen in demethylsterigmatocystin. The next two steps in the biosynthetic pathway is the methylation by S-adenosyl methionine (SAM) of the two hydroxyl groups on the xanthone part of demethysterigmatocystin by two different methyltransferases, OmtB and OmtA. This yields O-methylsterigmatocystin. In the final steps there is an oxidative cleavage of the aromatic ring and loss of one carbon in O-methylsterigmatocystin, which is catalyzed by OrdA, an oxidoreductase. Then a final recyclization occurs to form aflatoxin B1.
Sources: en.wikipedia.org
The Association for Laboratory Medicine (previously the Association for Clinical Biochemistry and Laboratory Medicine) is a United Kingdom-based learned society dedicated to the practice and promotion of laboratory medicine which consists of the clinical biochemistry, immunology and microbiology professions. It was founded on 28 March 1953 at the inaugural meeting attended by 75 members at the Hammersmith Hospital in London, and its official journal is the Annals of Clinical Biochemistry. The association is a full, national society member of the International Federation of Clinical Chemistry and Laboratory Medicine IFCC as well as a full member of the regional European Federation of Clinical Chemistry and Laboratory Medicine. Its qualifying members are automatically members of the certificated trade union called Federation of Clinical Scientists (FCS), which represents the interests of clinical scientists. Some members who meet the eligibility criteria are enrolled to the register of European Specialists in Laboratory Medicine (EuSpLM).
==== Types of protectants ==== Acetals and Ketals – Removed by acid. Normally, the cleavage of acyclic acetals is easier than of cyclic acetals. Acylals – Removed by Lewis acids. Dithianes – Removed by metal salts or oxidizing agents.
The physiology of cardiac muscle shares many similarities with that of skeletal muscle. The primary function of both muscle types is to contract, and in both cases, a contraction begins with a characteristic flow of ions across the cell membrane known as an action potential. The cardiac action potential subsequently triggers muscle contraction by increasing the concentration of calcium within the cytosol.
Langer's lines, Langer lines of skin tension, or sometimes called cleavage lines, are topological skin lines drawn on a map of the human body. They are parallel to the natural orientation of collagen fibers in the dermis, and generally parallel to the underlying muscle fibers. Langer's lines have relevance to forensic science and the development of surgical techniques.
Sources: en.wikipedia.org
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.
The peptide and its copper form have been detected in human plasma, saliva, and urine. Early reports describe levels that fall with age. The functional meaning of these pools is still debated.
Chromatographic separation gives peptide purity, often reported as a percentage. Copper content is checked by a separate elemental method. Moisture and counter-ions may be reported as well.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.